WHO consolidated guidelines on tuberculosis 2020 moving toward fully oral regimen: Should country act in hurry?
作者信息
Jain Nirmal Kumar
机构信息
Department of Respiratory Medicine, JNU Medical College, Jaipur, Rajasthan, India.
出版信息
Lung India. 2021 Jul-Aug;38(4):303-306. doi: 10.4103/lungindia.lungindia_982_20.
Abstract
摘要
相似文献
1
WHO consolidated guidelines on tuberculosis 2020 moving toward fully oral regimen: Should country act in hurry?
Lung India. 2021 Jul-Aug;38(4):303-306. doi: 10.4103/lungindia.lungindia_982_20.
3
Effectiveness and safety of fully oral modified shorter treatment regimen for multidrug-resistant tuberculosis in Georgia, 2019-2020.
Monaldi Arch Chest Dis. 2021 Jan 14;91(1). doi: 10.4081/monaldi.2021.1679.
4
Impact of the change from an injectable to a fully oral regimen on patient adherence to ambulatory tuberculosis treatment in Dar es Salaam, Tanzania.
Tuber Lung Dis. 1995 Aug;76(4):286-9. doi: 10.1016/s0962-8479(05)80025-5.
7
[Human rights of patients and tuberculosis prevention].
Kekkaku. 2008 Feb;83(2):111-4.
9
World Health Organization 2018 treatment guidelines for rifampicin-resistant tuberculosis: uncertainty, potential risks and the way forward.
Int J Antimicrob Agents. 2020 Jan;55(1):105822. doi: 10.1016/j.ijantimicag.2019.10.003. Epub 2019 Oct 15.
10
[Interpretation of WHO consolidated guidelines on tuberculosis module 4: drug resistant tuberculosis treatment].
Zhonghua Jie He He Hu Xi Za Zhi. 2021 Apr 12;44(4):349-353. doi: 10.3760/cma.j.cn112147-20200709-00786.
引用本文的文献
1
Newer research transforming 24-month treatment of MDR/XDR-TB TO 6 months.
Lung India. 2025 Mar 1;42(2):140-146. doi: 10.4103/lungindia.lungindia_431_24. Epub 2025 Feb 27.
2
Reply: Roll out of bedaquiline without drug susceptibility testing leads to emergence of bedaquiline-resistance in high burden countries with tuberculosis - Danger of losing a novel drug.
Lung India. 2022 Jul-Aug;39(4):389-390. doi: 10.4103/lungindia.lungindia_31_22.
3
India should speed up access to bedaquiline-based all-oral regimens, not procrastinate further.
Lung India. 2021 Nov-Dec;38(6):590-591. doi: 10.4103/lungindia.lungindia_425_21.
本文引用的文献
1
Drug-associated adverse events in the treatment of multidrug-resistant tuberculosis: an individual patient data meta-analysis.
Lancet Respir Med. 2020 Apr;8(4):383-394. doi: 10.1016/S2213-2600(20)30047-3. Epub 2020 Mar 17.
2
Management of multidrug-resistant tuberculosis with shorter treatment regimen in Niger: Nationwide programmatic achievements.
Respir Med. 2020 Jan;161:105844. doi: 10.1016/j.rmed.2019.105844. Epub 2019 Nov 23.
3
Short-Course Regimen for Multidrug-Resistant Tuberculosis: A Decade of Evidence.
J Clin Med. 2019 Dec 25;9(1):55. doi: 10.3390/jcm9010055.
4
Multidrug-resistant tuberculosis.
Lancet. 2019 Jul 27;394(10195):299. doi: 10.1016/S0140-6736(19)30046-7.
5
A Trial of a Shorter Regimen for Rifampin-Resistant Tuberculosis.
N Engl J Med. 2019 Mar 28;380(13):1201-1213. doi: 10.1056/NEJMoa1811867. Epub 2019 Mar 13.
6
Efficacy and safety of delamanid in combination with an optimised background regimen for treatment of multidrug-resistant tuberculosis: a multicentre, randomised, double-blind, placebo-controlled, parallel group phase 3 trial.
Lancet Respir Med. 2019 Mar;7(3):249-259. doi: 10.1016/S2213-2600(18)30426-0. Epub 2019 Jan 7.
7
Treatment correlates of successful outcomes in pulmonary multidrug-resistant tuberculosis: an individual patient data meta-analysis.
Lancet. 2018 Sep 8;392(10150):821-834. doi: 10.1016/S0140-6736(18)31644-1.
8
Improved Treatment Outcomes With Bedaquiline When Substituted for Second-line Injectable Agents in Multidrug-resistant Tuberculosis: A Retrospective Cohort Study.
Clin Infect Dis. 2019 Apr 24;68(9):1522-1529. doi: 10.1093/cid/ciy727.
9
Principles for constructing a tuberculosis treatment regimen: the role and definition of core and companion drugs.
Int J Tuberc Lung Dis. 2018 Mar 1;22(3):239-245. doi: 10.5588/ijtld.17.0660.
10
Safety and efficacy of exposure to bedaquiline-delamanid in multidrug-resistant tuberculosis: a case series from France and Latvia.
Eur Respir J. 2018 Mar 22;51(3). doi: 10.1183/13993003.02550-2017. Print 2018 Mar.
Zotero 插件